LifeTech Scientific Corporation (HK:1302)
:1302
Top Page
LifeTech Scientific Corporation
(1302)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$2.00
▲(26.58% Upside)
Action:ReiteratedDate:12/11/25
The overall stock score is primarily influenced by strong financial performance, despite challenges in margins and cash flow. Technical analysis indicates bearish momentum, and the high valuation suggests limited upside. The absence of earnings call and corporate events data means these factors do not impact the score.
Positive Factors
Revenue Growth Trend
Consistent top-line expansion over 2019–2024 indicates durable demand for LifeTech’s cardiovascular and orthopedic devices and effective commercial execution. Sustained revenue growth supports scale benefits, funds ongoing R&D and geographic expansion, and strengthens competitive positioning over multiple years.
Negative Factors
Declining Operating Margins
Eroding EBIT and net margins indicate rising operating costs or weakened pricing power that can materially reduce free cash generation. Persistent margin compression would limit capacity to fund R&D and commercial expansion internally, making long-term earnings growth and competitiveness harder to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trend
Consistent top-line expansion over 2019–2024 indicates durable demand for LifeTech’s cardiovascular and orthopedic devices and effective commercial execution. Sustained revenue growth supports scale benefits, funds ongoing R&D and geographic expansion, and strengthens competitive positioning over multiple years.
Read all positive factors
LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.86B
Dividend YieldN/A
Average Volume (3M)26.58M
Price to Earnings (P/E)36.5
Beta (1Y)0.91
Revenue Growth3.42%
EPS Growth-70.82%
CountryHK
Employees1,395
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.85
Price to Book (P/B)1.64
Price to Sales (P/S)4.39
P/FCF Ratio148.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.53B
LifeTech Scientific Corporation Business Overview & Revenue Model
Company Description
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart D...
How the Company Makes Money
LifeTech Scientific Corporation generates revenue primarily through the sale of its medical devices and related products. The company's key revenue streams include direct sales of its cardiovascular devices, orthopedic implants, and surgical instr...
LifeTech Scientific Corporation Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33B | 1.30B | 1.27B | 1.10B | 925.33M | 642.30M |
| Gross Profit | 963.81M | 981.43M | 995.64M | 873.93M | 747.53M | 513.14M |
| EBITDA | 134.22M | 271.87M | 253.46M | 445.78M | 397.59M | 314.14M |
| Net Income | 71.91M | 222.39M | 263.24M | 325.34M | 292.47M | 216.09M |
Balance Sheet | ||||||
| Total Assets | 5.33B | 4.90B | 4.70B | 3.69B | 3.18B | 2.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 1.18B | 1.18B | 833.79M | 1.48B | 1.14B |
| Total Debt | 3.91M | 4.98M | 9.30M | 9.67M | 15.67M | 185.98M |
| Total Liabilities | 1.60B | 1.42B | 1.37B | 769.05M | 653.61M | 596.06M |
| Stockholders Equity | 3.77B | 3.49B | 3.37B | 2.90B | 2.50B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | 572.83M | 38.46M | 125.36M | 52.84M | 145.57M | 180.15M |
| Operating Cash Flow | 610.06M | 321.46M | 418.05M | 388.32M | 488.85M | 338.53M |
| Investing Cash Flow | -566.23M | -517.53M | -453.88M | -458.47M | -86.76M | -341.63M |
| Financing Cash Flow | -92.84M | -116.97M | 182.71M | -215.20M | -256.38M | 674.66M |
LifeTech Scientific Corporation Technical Analysis
Positive
1.58
Price Trends
1.71
Positive
1.72
Positive
1.85
Negative
Market Momentum
0.02
Negative
60.28
Neutral
68.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Positive. The current price of 1.58 is below the 20-day moving average (MA) of 1.72, below the 50-day MA of 1.71, and below the 200-day MA of 1.85, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.28 is Neutral, neither overbought nor oversold. The STOCH value of 68.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1302.
LifeTech Scientific Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$6.32B | 31.02 | 11.84% | 1.50% | -5.18% | -9.69% | |
58 Neutral | HK$8.16B | 27.86 | 4.88% | 0.48% | 35.01% | 483.73% | |
57 Neutral | HK$7.86B | 36.52 | 1.98% | ― | 3.42% | -70.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$17.58B | -9.88 | -26.71% | ― | -1.04% | 60.66% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:1302
LifeTech Scientific Corporation
1.82
0.51
38.93%
HK:0853
MicroPort Scientific
9.17
2.61
39.79%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
23.70
9.58
67.87%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2172
MicroPort NeuroTech Limited
10.81
1.72
18.92%
LifeTech Scientific Corporation Corporate Events
LifeTech Scientific Director Resigns as Company Moves to Restore Governance Compliance
Jan 26, 2026
LifeTech Scientific Corporation announced the resignation of independent non-executive director Wang Wansong, who is stepping down effective 26 January 2026 after serving more than nine years, in order to comply with Hong Kong Stock Exchange requi...
LifeTech Scientific Outlines Board Composition and Committee Structure
Jan 26, 2026
LifeTech Scientific Corporation has announced the current composition of its board of directors, detailing five executive directors, one non-executive director and two independent non-executive directors, led by Chairman and Chief Executive Office...
LifeTech Stent-Graft System Enters China’s Fast-Track Approval for Innovative Aortic Arch Devices
Jan 12, 2026
LifeTech Scientific has received confirmation from China’s National Medical Products Administration that its Concave Supra-arch Branched Stent-Graft System has been admitted into the special examination and approval procedure for innovative ...
LifeTech Wins China NMPA Approval for Upgraded G-iliac Pro Iliac Artery Stent Graft
Jan 8, 2026
LifeTech Scientific Corporation announced that its independently developed G-iliac™ Pro iliac artery stent graft system has received official registration approval from China’s National Medical Products Administration, clearing the way...
LifeTech Scientific Announces Share Purchase for Award Scheme
Dec 9, 2025
LifeTech Scientific Corporation has entered into an agreement to purchase 230,000,000 shares from a substantial shareholder as part of its Share Award Scheme. This transaction, which involves a connected person under the Listing Rules, is valued a...
LifeTech Announces Board Reshuffle to Strengthen Governance
Nov 21, 2025
LifeTech Scientific Corporation has announced significant changes in its board of directors and committee compositions, effective November 21, 2025. Notably, Ms. Ruan Xingmei and Mr. Liang Hsien Tse Joseph have resigned from their respective direc...
LifeTech Scientific Announces Board Composition and Committee Formation
Nov 21, 2025
LifeTech Scientific Corporation has announced the composition of its board of directors and the establishment of three board committees: Audit, Remuneration, and Nomination. This organizational update reflects the company’s commitment to rob...
LifeTech’s G-Branch™ Stent Graft System Gains Approval in China
Nov 6, 2025
LifeTech Scientific Corporation announced that its G-Branch™ thoracoabdominal artery stent graft system has received official registration approval from the China National Medical Products Administration. This device, designed for the treatm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.